[Sponsored] Executives from EY, Geneon, ProviderTrust, SmarterDx, and symplr shared insights about their businesses in interviews at the ViVE 2025 conference in Nashville this month.
PepGen is one of several companies vying to bring to market the first treatment for the rare muscle disorder myotonic dystrophy type 1, or DM1. Preliminary Phase 1 data indicate its drug candidate is competitive with others further ahead in development.
Medicaid is probably the most innovative program in healthcare today. Its flexibility, adaptability, and focus on whole-person care have made it a leader in addressing the complex needs of vulnerable populations, and it offers useful examples of how to embrace true risk-based, value-based reimbursement.
It is time we realize that there is no single panacea for mental health; the need to break down barriers for working families and individuals in rural towns or underserved communities requires we move past a narrow definition of telehealth.
No comments